# Ovaprene (ovaprene) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ovaprene

> Ovaprene (ovaprene), sponsored by Dare Bioscience, Inc. (DARE): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ovaprene (ovaprene) |
| Codes |  |
| Sponsor | Dare Bioscience, Inc. (DARE) https://sec-api.dev/companies/dare/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001493152-24-045860): "National Institutes of Health (NIH) and commercial collaborator Bayer, Daré commenced patient enrollment in the Ovaprene® pivotal Phase 3 clinical study in December 2023." https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/ex99-1.htm

### Jul 2025: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-12-01, last confirmed 2025-12-01.
- Press release filed with the SEC (EX-99) (accession 0001493152-25-025491): "July 2025, Daré announced positive interim data from the ongoing open-label Phase 3 trial of Ovaprene (ClinicalTrials.gov" https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-025491): ""The Phase 3 study is progressing, supported by non-dilutive funding, and the positive interim data announced in July 2025 underscore the asset's potential." https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/ex99-1.htm

### May 14, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-05-14, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0001401914-26-000025): "Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update Your publication date and time will appear here. | Source: Daré Bioscience, Inc. Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week." https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/a260514q12026earningsupd.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ovaprene.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ovaprene (ovaprene) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ovaprene

```bibtex
@misc{secapidev_pdufa_ovaprene_20261116,
  title        = {Ovaprene (ovaprene) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ovaprene}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ovaprene_20261116","title":"Ovaprene (ovaprene) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ovaprene","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
